Views & Analysis New NICE processes – same old problem? Following two recent controversial public consultations, NICE recently updated its Guide to the Processes of Technology Appraisal.
News NICE says 'no' to Roche's Perjeta after breast cancer surger... NICE consulting on first draft decision
News Patients call for end to two-year row over CF drug funding UK patients are stepping up efforts to resolve the “heartbreaking” row that is denying their families access to Vertex’s groundbreaking cystic fibrosis (CF) drug Orkambi, after Sweden becam
News J&J's Tremfya gets funding in Germany and UK Johnson & Johnson’s psoriasis drug Tremfya has been given the green light for funding by cost-effectiveness bodies in the UK and Germany.
Views & Analysis Who should pay for HTA? Part of the drive for strengthening EU cooperation on health technology assessment (HTA) is to tackle duplication of work
News Lung cancer drug Keytruda to become routinely available on N... NICE has given the green light for lung cancer drug Keytruda to be used as a routine treatment for certain patients in England.
News Court sides with EU on decision to revoke Ocaliva's license Advanz Pharma's bid to keep its Ocaliva treatment for rare liver disease primary biliary cholangitis (PBC) on the EU market has ended in failure
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
